The Week

Resmed (RMD) gained 3.08% this week to close at $224.99, while the S&P 500 slipped 0.08%, leaving the stock about 3.16 percentage points ahead of the benchmark. The week opened at $221.04 and ran up to an intraday high of $234.33 on Tuesday, before settling back into a $224-229 range from Wednesday onward. Friday’s close at $224.99 trimmed a chunk of the earlier pop. Weekly amplitude reached 6.06%, and average daily volume of 1.73m shares ran about 31.9% above the 60-day median, so the tape was busier than usual.

Key Events

The story this week centred on a broker upgrade and sector rotation. Several outlets noted on Tuesday that the stock had outperformed the market the previous session, while Guggenheim lifted New York Times to buy — not an RMD catalyst in itself, but part of a broader hunt for relative strength across industries. On Tuesday, RBC Capital Markets raised Resmed to outperform. The stock pushed to its weekly high that day, but failed to extend the move over the next three sessions, with Friday’s pullback taking it briefly below $225. There were no company earnings or product announcements this week; the price action rode mostly on the rating change and shifting risk appetite in the medical device space.

Analyst Ratings

Twenty brokers now cover Resmed: 6 rate it buy, 2 overweight, 10 hold, 1 sell, and 1 has no opinion. The consensus rating is buy, with a consensus target of $247.5625, roughly 10.0% above the latest price. The target range is unusually wide — from $175 at the low end to $320 at the high end — suggesting splits in longer-term assumptions. Within the medical device industry, Resmed ranks 11th out of 142 covered names, solid but not in the top tier of broker preference.

The Week Ahead

Macro data picks up next week. Tuesday brings the Richmond Fed composite index, Wednesday has EIA crude and Cushing inventory reports, and Thursday clusters initial jobless claims, the current account balance, new home sales, and EIA natural gas storage. Resmed does not have earnings scheduled next week, but its valuation remains sensitive to rates and macro sentiment, so jobless claims and new home sales are the ones to watch on the demand side. After RBC’s upgrade this week, another question is whether the stock can hold the $225 area and whether money continues to rotate towards the name.

In Short

Resmed rose on expanding volume this week, with the move lining up in time with RBC’s upgrade to outperform. Yet the broker community itself remains split: a $320 top target versus $175 at the low end points to very different views on the company’s growth runway, and an industry rank of 11th means RMD sits outside the most favoured tier. The latest trading day’s flow data shows net buying from both medium and small lots, though that snapshot covers only one day rather than a weekly trend. The next test is whether the post-upgrade price can hold near $225, and whether the week’s macro prints disturb risk appetite across the medical device complex.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.